Company
Introduction
Strand Life Sciences – Pioneers in Discovery Research Informatics, is a premier life science informatics innovation company. Strand leverages its core strengths and intellectual property in data mining, predictive modeling, bioinformatics, and computational chemistry to develop products and solutions for drug discovery.
Five of the top ten pharmaceutical companies, three of the top six biotechnology companies, and numerous academic institutions across the globe, are part of Strand's customer profile, who trust Strand for delivering solutions to complex problems in life sciences research.
- 2010 BIO-IT Conference
Apr 20-22, 2010
Strand at BIO-IT 2010, Boston.
The Strand exhibit
Francois Mandeville presenting the vendor presentation
Dr. Vijay Chandru presenting the iPad to the winner of the lucky draw, Mr. Lionel Zupan, Director, Research Technology Services UIT Academic Technology, Tufts University. Congratulations!
- Strand and Narayana Hrudalaya Collaborate in Translational Cancer Research.
First-of-its kind project in translational cancer research aimed to produce pioneering discoveries and affordable clinical solutions in cancer care.
August 18, 2010, Bangalore, India - Strand Life Sciences (Strand), a technology pioneer in the practice of scientific intelligence in health sciences, today announced that it has signed an MOU with Mazumdar Shaw Comprehensive Cancer Centre (MSCC) of the Narayana Hrudalaya (NH), in translational cancer research. The partner...
- Options in Genome Analysis - June 01, 2010
Web-based tools, traditional software, and instrument-based analysis move genome-wide analysis forward several steps.
James Netterwald, PhD, Contributing Editor
Drug Discovery & Development Publication
Figure. Screen capture from the Genomics Reviewer Desktop (GRD), built on the Avadis platform. (Source: Strand Life Sciences)
Read More
- Strand Develops Genomic Reviewer Desktop Solution for the FDA
Press Release, May 03, 2010, San Francisco, California
Strand Life Sciences (Strand), a pioneer in scientific intelligence, today announced that it has entered into an agreement with the U.S. Food and Drug Administration (FDA) to deliver the Genomics Reviewer Desktop (GRD), a solution to enable FDA reviewers to manage and analyze pharmacogenomic data submitted through its Voluntary Exploratory Data Submissions (VXDS) program. GRD will enable FDA to integrate analyse...